Alexander Jones

Mr. Alexander Jones

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2014 in Toxicology Letters
Verified
Journal Article
Closed access
SOStefanie L. O’neal
Stefanie L. O’neal
LHLan Hong
Lan Hong
SFSherleen Fu
Sherleen Fu
WJWendy Jiang
Wendy Jiang
AJAlexander Jones
Alexander Jones
WZWei Zheng
Wei Zheng

30 April 2019 in Journal of Trauma and Acute Care Surgery
Verified
Journal Article
Closed access
JDJoao D. Dias
Joao D. Dias
CLCarlos G. Lopez-Espina
Carlos G. Lopez-Espina
JIJeffrey Ippolito
Jeffrey Ippolito
LHL. Hsiuyin Hsiao
L. Hsiuyin Hsiao
FZFowzia Zaman
Fowzia Zaman
HAHardean E. Achneck
Hardean E. Achneck
BACKGROUND: The trauma patient on direct oral anticoagulant (DOAC) therapy preinjury presents a challenge in trauma and acute care surgery. Our understanding of these patients is extrapolated from vitamin K antagonists. However, DOACs have different mechanisms of action, effects on laboratory coagulation assays, and reversal strategies. Rapid identification of DOACs in the blood will allow timely reversal of factor Xa inhibitors and direct thrombin inhibitors when necessary. The present study evaluated viscoelastic testing to detect and classify DOACs in patient blood samples.METHODS: This observational, prospective, open-label, multicenter study used point-of-care viscoelastic testing to analyze blood samples taken from patients with and without DOAC treatment, and healthy volunteers. Antifactor Xa and direct thrombin inhibition (DTI) assays were used to establish reference ranges for viscoelastic testing parameters on the TEG 6s system. These ranges were applied to produce a DOAC identification algorithm for patient blood samples. Internal consistency of the measurements, as well as algorithm sensitivity and specificity, was evaluated.RESULTS: Using the TEG 6s system, the R parameter reference range was 0.6 minutes to 1.5 minutes for the Antifactor Xa assay and 1.6 minutes to 2.5 minutes for the DTI assay. Our identification algorithm using these ranges for 2.5 minutes or less has sensitives of 98.3% and 100% for factor Xa inhibitor and direct thrombin inhibitor detection, respectively. Specificity was 100%. Both classes of DOAC were detectable, even when samples were collected during the “trough” between doses of medication.CONCLUSION: Point-of-care viscoelastic testing with TEG 6s can detect and classify DOACs with high sensitivity and specificity. This tool can be used to better determine the need for reversal in trauma and acute care surgery patients and guide optimal surgical timing in the acute setting.LEVEL OF EVIDENCE: Prognostic and epidemiological study, level II.

23 February 2020 in Journal of Reconstructive Microsurgery
Verified
Journal Article
Closed access
PDF file
AJAlexander Jones
Alexander Jones
MAMohamedkazim M. Alwani
Mohamedkazim M. Alwani
LNLeah J. Novinger
Leah J. Novinger
EPEric Pittelkow
Eric Pittelkow
ABAndrea Bonetto
Andrea Bonetto
AMAvinash V. Mantravadi
Avinash V. Mantravadi
Background Sarcopenia has been implicated as a positive predictor of postsurgical complications. Its role in head and neck (H&N) free flap reconstruction has yet to be examined. Our study aimed to determine the clinical impact of sarcopenia on postoperative outcomes in patients receiving autologous free tissue reconstruction for H&N cancer (HNC). Methods A retrospective case–control study was conducted at our tertiary referral center. Patients with HNC who received oncologic resection followed by autologous free tissue reconstruction were included. Preoperative abdominal computed tomography (CT) imaging was analyzed at the third lumbar vertebra (L3) to calculate skeletal muscle cross-sectional area (CSA, cm2). Skeletal muscle index (SMI, cm2/m2) was calculated by normalizing CSA to patient height. Sarcopenia at L3 was defined as SMI ≤ 41.6 cm2/m2 for males and ≤ 32.0 cm2/m2 for females. Data analyses were performed to compare postoperative outcomes. Results Of the 168 patients who met inclusion criteria, 47 patients (28.0%) were determined to have preoperative sarcopenia. The sarcopenic group was older (63 vs. 58 years, p = 0.017), had lower body mass index (BMI; 21.2 vs. 27.2, p < 0.001), had greater incidence of alcohol abuse (55.3 vs. 23.1%, OR = 4.11, p < 0.001). Intraoperatively, sarcopenic patients were found to have greater rates of blood transfusions (63.8 vs. 29.8%, p < 0.001). Postoperatively, sarcopenic patients had higher rates of pneumonia (p < 0.01), venous thromboembolism (p < 0.01), prolonged ventilation (p < 0.01), delirium (p < 0.01), fistula (p < 0.05), wound disruption (p < 0.05), and longer intensive care unit stays (p < 0.05). Sarcopenic patients were ultimately found to have higher overall rates of general postoperative complications (p < 0.001) and flap-specific complications (p < 0.01). Conclusion Sarcopenia was found to be a predictor of postoperative complications in H&N free flap reconstruction, signifying its value as a negative prognostic factor in surgical outcomes. This study reflects level of evidence IV. * Contributed equally to this work.

13 December 2021 in Journal of Bone and Mineral Research
Verified
Journal Article
Open access
PDF file
FPFabrizio Pin
Fabrizio Pin
AJAlexander Jones
Alexander Jones
JHJoshua R Huot
Joshua R Huot
ANAshok Narasimhan
Ashok Narasimhan
TZTeresa A Zimmers
Teresa A Zimmers
ABAndrea Bonetto
Andrea Bonetto
Tumor- and bone-derived soluble factors have been proposed to participate in the alterations of skeletal muscle size and function in cachexia. We previously showed that mice bearing ovarian cancer (OvCa) exhibit cachexia associated with marked bone loss, whereas bone-targeting agents, such as bisphosphonates, are able to preserve muscle mass in animals exposed to anticancer drugs. De-identified CT images and plasma samples from female patients affected with OvCa were used for body composition assessment and quantification of circulating cross-linked C-telopeptide type I (CTX-I) and receptor activator of NF-kB ligand (RANKL), respectively. Female mice bearing ES-2 tumors were used to characterize cancer- and RANKL-associated effects on muscle and bone. Murine C2C12 and human HSMM myotube cultures were used to determine the OvCa- and RANKL-dependent effects on myofiber size. To the extent of isolating new regulators of bone and muscle in cachexia, here we demonstrate that subjects affected with OvCa display evidence of cachexia and increased bone turnover. Similarly, mice carrying OvCa present high RANKL levels. By using in vitro and in vivo experimental models, we found that elevated circulating RANKL is sufficient to cause skeletal muscle atrophy and bone resorption, whereas bone preservation by means of antiresorptive and anti-RANKL treatments concurrently benefit muscle mass and function in cancer cachexia. Altogether, our data contribute to identifying RANKL as a novel therapeutic target for the treatment of musculoskeletal complications associated with RANKL-expressing non-metastatic cancers. © 2021 American Society for Bone and Mineral Research (ASBMR). Abstract RANKL directly impairs muscle mass and function in cancer cachexia. Tumor-derived factors, including RANKL, drive bone resorption in non-bone metastatic cancer. Blockade of RANKL and cancer-associated bone resorption results in improved muscle mass and function, even in the absence of bone metastases.

31 January 2021 in Laryngoscope Investigative Otolaryngology
Verified
Journal Article
Open access
PDF file
AJAlexander Jones
Alexander Jones
VCVincent J. Campiti
Vincent J. Campiti
MAMohamedkazim Alwani
Mohamedkazim Alwani
LNLeah J. Novinger
Leah J. Novinger
BTBrady Jay Tucker
Brady Jay Tucker
AMAvinash V. Mantravadi
Avinash V. Mantravadi
Objective: To determine if sarcopenia is a predictor of blood transfusion requirements in head and neck cancer free flap reconstruction (HNCFFR).Methods: A single‐institution, retrospective review was performed of HNCFFR patients with preoperative abdominal imaging from 2014 to 2019. Demographics, comorbidities (modified Charlson Comorbidity Index [mCCI]), skeletal muscle index (cm2/m2), oncologic history, intraoperative data, and 30‐day postoperative complications (Clavien‐Dindo score [CD]) were collected. Binary logistic regression was performed to determine predictors of transfusion.Results: Eighty (33.5%), 66 (27.6%), and 110 (46.0%) of n = 239 total patients received an intraoperative, postoperative, or any perioperative blood transfusion, respectively. Sixty‐two (25.9%) patients had sarcopenia. Patients receiving intraoperative transfusions had older age (P = .035), more frequent alcoholism (P = .028) and sarcopenia (P < .001), greater mCCI (P < .001), lower preoperative hemoglobin (P < .001), reconstruction with flaps other than forearm (P = .003), and greater operative times (P = .001), intravenous fluids (P < .001), and estimated blood loss (EBL, P < .001). Postoperative transfusions were associated with major complications (CD ≥ 3; P < .001). Multivariate regression determined sarcopenia (P = .023), mCCI (P = .013), preoperative hemoglobin (P = .002), operative time (P = .036), and EBL (P < .001) as independent predictors of intraoperative transfusion requirements. Postoperative transfusions were predicted by preoperative hemoglobin (P = .007), osseous flap (P = .036), and CD ≥ 3 (P < .001). A perioperative transfusion was predicted by sarcopenia (P = .021), preoperative hemoglobin (P < .001), operative time (P = .008), and CD ≥ 3 (P = .018).Conclusion: Sarcopenia is associated with increased blood transfusions in HNCFFR. Patients should be counseled preoperatively on the associated risks, and the increased blood product requirement should be accounted in resource‐limited scenarios.Level of Evidence: 4.

8 December 2020 in Otolaryngology–Head and Neck Surgery
Verified
Journal Article
Closed access
PDF file
AJAlexander Jones
Alexander Jones
VCVincent Joseph Campiti
Vincent Joseph Campiti
MAMohamedkazim Alwani
Mohamedkazim Alwani
LNLeah J. Novinger
Leah J. Novinger
ABAndrea Bonetto
Andrea Bonetto
AMAvinash V. Mantravadi
Avinash V. Mantravadi